There is a pressing need for sustainable and sensitive immunodiagnostics for use in public health 15 efforts to understand and combat the threat of endemic and emerging infectious diseases. We 16 describe a novel approach to immunodiagnostics based on virus-like particles (VLPs) attached to 17 magnetic beads. This flexible, innovative immunoassay system, based on the MAGPIX® 18 platform, improves sensitivity by up to 2-logs and has faster sample-to-answer time over 19 traditional methods. As a proof of concept, a retroviral-based VLP, that presents the Venezuelan 20 equine encephalitis virus E1/E2 glycoprotein antigen on its surface, was generated and coupled 21 2 to magnetic beads to create VLP-conjugated microspheres (VCMs). Using these VCMs, IgG and 22
Introduction 32
Immunoassays are the standard for preliminary and confirmatory diagnosis of infectious and 33 non-infectious diseases, since they are reliable, robust, and accessible by many diagnostic 34 laboratories. In disease outbreaks, diagnostics are the first line of defense in identification of the 35 causative agent, treatment decisions, and eventually control and prevention of future outbreaks. 36
An integrated diagnostic system that uses sensitive and specific molecular assays (e.g. PCR) in 37 combination with less sensitive, but more broadly-reactive immunodiagnostic methods (e.g. 38 ELISA) provides the highest confidence in a diagnostic result (1-3). Immunoassays are designed 39 to detect protein-based antigens and antibodies, with antigen detection assays relying heavily on 40 agent-specific monoclonal antibodies, and antibody detection assays requiring structurally 41 accurate agent-specific antigens. While these immunodiagnostic technologies are relatively 42 unsophisticated, development of sensitive and specific antibodies and antigens required for an 43 immunoassay is often a rate-limiting step. These immunodiagnostic reagents must be sensitive, 44 specific, robust, and most importantly, sustainable (4). 45
Sustainability is the most problematic issue for immunodiagnostic reagent development. A 46 frequent viral antigen target of interest for many immunoassays is surface glycoproteins (5, 6) . 47
Traditionally, detection of anti-viral glycoprotein humoral responses for both serosurveillance 48 and clinical diagnosis are determined by direct immunoassay methods using inactivated whole 49 virus or lysates from infected cells to capture virus-specific antibodies in a sample. Use of whole 50 virus for many pathogenic agents is challenging as assays must be conducted in high level 51 biological containment (biosafety level [BSL] 3 or 4). Inactivated virus can be utilized at the 52 BSL2 level, but vital epitopes are sometimes destroyed after inactivation protocols (7). 53
Recently, recombinant proteins have been used as substitutes for virus preparation because they 54 do not require specialized facilities for production, isolation, and use, and thus are more 55 sustainable. However, soluble recombinant glycoproteins can have substantial caveats, such as 56 the need for truncation to facilitate soluble release of the recombinant protein, artificial protein 57 structure due to the lack of a membrane anchor or improper folding, and/or complete resistance 58 to recombinant expression due to heterodimeric or complex maturation behavior (8) (9) (10) (11) (12) . To 59 circumvent these issues, an ideal diagnostic reagent would present glycoprotein antigens to the 60 analyte material in the context of an authentic viral envelope structure while still being safe to 61 use at the BSL2 level. In lieu of native virus, an alternate strategy for sustainable glycoprotein 62 production can be achieved through the use of virus-like particles (VLPs). VLP generation 63 typically relies on expression of self-assembling viral matrix proteins (e.g. HIV Gag or Ebola 64 virus VP40) that drive particle formation via self-to-self oligomerization as well as recruitment 65 of host cell machinery involved in vesicle formation and/or the secretory pathway (e.g. ESCRT 66 complexes) (13). These particles are extremely safe since they contain no viral genome and can 67 be versatile platforms for glycoprotein antigen presentation due to their well-documented ability 68 to integrate both homologous and heterologous glycoproteins during their budding through the 69 plasma membrane (14, 15) . For analytical approaches solely dependent on reactivity, VLPs are a 70 desirable reagent because of their ease of manufacture, antigenic fidelity, and lack of safety 71 concerns. 72
Not only is development of immunoassay reagents critical when designing sustainable 73 immunodiagnostic assays, but equally important is the choice of platform. While the traditional 74 96-well plate ELISA has served as a workhorse for serosurveillance efforts for decades, several 75 immunoassay platforms have emerged to make patient sample analysis faster, more sensitive, 76 and multiplexed at both point-of-care and centralized laboratories. One such system is the 77 MAGPIX® developed by Luminex Corporation (Austin, Texas USA) (16). It is similar to 78 ELISA in that it detects a typical antigen/antibody interaction, but by employing fluorescently 79 labeled magnetic particles as a solid support, MAGPIX assays are much faster, have increased 80 sensitivity, and better enable multiplexing (17, 18) . This ability to multiplex while maintaining 81 assay sensitivity is crucial for effective serosurveillance efforts to understand and control the 82 spread of disease. 83
Herein, we outline the design and implementation of a novel diagnostic reagent, which pairs the 84 sustainability of a VLP with the sensitivity of the MAGPIX platform to serve as a versatile tool 85 for detection of anti-viral glycoprotein humoral responses in a serum sample (Figure 1 ). More 86 specifically, we focused on production, characterization, and optimization of alphavirus 87 diagnostic reagents, due to previously documented problems associated with recombinant 88 expression of their E1/E2 heterodimeric glycoproteins and because these glycoproteins play a 89 dominant role in host immune response during alphavirus infection (19) (20) (21) 
Materials and Methods 105

Antibodies and Sera 106
For ELISA and immuno-electron microscopy (IEM) analysis of VEEV VLPs, monoclonal 107 antibodies (mAbs) against VEEV envelope glycoproteins E1 (3B2A9) (22) or E2 (MAB 8767, 108 EMD Millipore, Burlington, MA, USA) were used. A mAb against VSV-G glycoprotein, 109 (1E9F9) I14, was used as a negative control. Positive and negative control sera from NHPs 110 vaccinated with either VEEV, EEEV, or WEEV E1/E2 plasmid DNA were generated as 111 described previously (23). All human sera used were previously deidentified and given a 112 "research not involving human subjects" determination. VEEV, EEEV, WEEV, and CHIKV IgG 113 and IgM positive sera originated from either vaccination or natural infection. 114
VLP Production 115
Plasmids encoding codon-optimized glycoprotein genes (E3-E2-6K-E1) of VEEV IAB (strain 116
Trinidad donkey), EEEV (strain FL91-4679), and WEEV (strain CBA87) inserted into the 117 mammalian expression pWRG7077 have been previously described (23, 24) . For the 118 construction of the Gag-encoding plasmid, the first 538 residues of murine leukemia virus 119 (MLV) Gag-Pol ORF (GenBank: AF033811.1) were codon optimized, synthesized, and cloned 120 into pWRG7077 using flanking 5' NotI and 3' BglII restriction sites relative to the transgene 121 insert (Atum Inc, Menlo Park, CA, USA). HEK293T cells were seeded in T150 flasks (Corning, 122 Inc., Corning, NY, USA) and incubated at 37°C with 5% CO 2 until reaching 70-80% confluency 123 prior to transfection with 27 µg of pWRG7077-Gag and 9 µg of pWRG7077-VEEV, 124 pWRG7077-EEEV, or pWRG7077-WEEV E1/E2 plasmid DNA using Fugene 6 (Roche, 125 Indianapolis, IN, USA) according to manufacturer's instructions. Cell supernatants were 126 collected at 24 and 48 h post-transfection, pooled, clarified by centrifugation, and filtered 127 through a 0.45 µm filter. VLPs were concentrated through a Centricon® filter unit with a 100-128 kDa cutoff (EMD Millipore, Burlington, MA, USA) according to manufacturer's instructions. 129
VLPs were then pelleted through a 20% sucrose cushion in virus resuspension buffer (VRB; 130 130 mM NaCl, 20 mM HEPES, pH 7.4) by centrifugation for 2 h at 106,750 × g in an SW32 rotor at 131 4°C. VLP pellets were resuspended overnight in VRB at 4°C, pooled, and diluted ten-fold with 132 VRB. The diluted VLPs were re-pelleted without a sucrose cushion as described above. VLPs 133 were resuspended in 1/1,000 volume of VRB relative to starting supernatant and then stored at -134
80°C. 135
CHIKV VLPs were produced in a manner that has been previously described (25). Briefly, a 136 DNA construct encoding the capsid-E3-E2-6K-E1 structural protein genes of CHIKV (strain 137 0706aTw) was synthesized and cloned into pWRG7077. HEK 293T cells were then transfected 138 with 25 µg of the VLP construct using Fugene 6 as described earlier. Supernatants were 139 harvested at 24, 48, and 72 h post-transfection and were purified as previously described. Protein 140 concentration for all VLPs was determined by BCA assay (ThermoFisher, Waltham, MA, USA). 141
Conjugation of VLPs to Magnetic Microspheres 142
VEEV, EEEV, WEEV, and CHIKV VLPs were conjugated to magnetic microspheres using the 143 Luminex xMAP® antibody coupling kit (Luminex Inc., Austin, TX, USA) according to the 144 manufacturer's instructions. Briefly, 100 µL of Magplex microspheres (12.5 × 10 6 145 microspheres/mL) were washed three times using a magnetic microcentrifuge tube holder and 146 resuspended with 480 µL of activation buffer. Then, 10 µL of both sulfo-NHS and EDC 147 solutions were added to the resuspended microspheres. The tube was covered with aluminum foil 148 and placed on a benchtop rotating mixer for 20 min. After surface activation with EDC, the 149 microspheres were washed three times with activation buffer prior to adding the VLPs at a final 150 concentration of 10 µg VLPs/1 × 10 6 microspheres. The tube was again covered with aluminum 151 foil and placed on a benchtop rotating mixer for 2 h. After this coupling step, the microspheres 152 were washed three times with wash buffer and resuspended in wash buffer to the original stock 153 concentration of 12.5 × 10 6 microspheres/mL for further use. The VLPs were conjugated to 154
Magplex microsphere regions #75, #15, #45, and #25 (Luminex Inc., Austin, TX, USA), 155 respectively, in order to facilitate multiplexing experiments. 156
Detection of anti-viral IgG or IgM in NHP or Human Sera using VLP-coupled Magplex 157
Microspheres 158 VCMs were diluted 1:250 in phosphate buffer saline (PBS) with 0.02% Tween-20 (PBST) and 159 added to the wells of a Costar polystyrene 96-well plate at 50 µL per well (2500 160 microspheres/well). The plate was placed on a Luminex plate magnet, covered with foil, and 161 microspheres were allowed to collect for 60 sec. While still attached to the magnet, the buffer 162 was removed from the plate by shaking. Then, 50 µL of serum, diluted in PBST with 5% skim 163 milk (PBST-SK) was added to appropriate wells and the plate was covered and incubated with 164
shaking for 1 h at room temperature (RT). The plate was washed three times with 100 µL of 165 PBST using the plate magnet to retain the Magplex microspheres in the wells and then 50 µL of 166 a 1:100 dilution of goat anti-human IgG (H&L) phycoerythrin conjugate (Sigma-Aldrich, St. 167
Louis, MO, USA) or goat anti-human IgM (anti-mu) phycoerythrin conjugate (Abcam, 168 Cambridge, UK) in PBST-SK were added to the wells. The plate was covered and incubated 169 with shaking for 1 h at RT. After incubation, the plate was washed three times and the Magplex 170 microspheres were resuspended in 100 µL of PBST for analysis on the MAGPIX. For 171 multiplexed experiments, the VLP-coupled microspheres were each added to the plate so that 172 2500 microspheres of each VCM set were dispensed per well. The remainder of the multiplexed 173 assay was performed as described above. For sera from VEEV, EEEV, and WEEV-infected 174
NHPs, analysis was conducted in a BSL-3 suite with infected material handled in a Class II 175
Biological Safety Cabinet. All samples were run in triplicate. 176
Results 177
Synthesis and Characterization of VLPs 178
MLV-based VLPs were chosen for VEEV glycoprotein presentation because they are high 179 yielding, homogenous, and can accommodate a wide range of glycoprotein antigens (26, 27) . 180
Transient expression of two DNA plasmids encoding both VEEV E1/E2 and the first 538 amino 181 acids of MLV Gag in mammalian cells generated highly homogenous particles presenting both 182 the E1 and E2 VEEV glycoproteins on their surface as determined by electron microscopy 183 (Figure 2A, B) . A molar ratio of 3:1 Gag plasmid to VEEV E1/E2 plasmid yielded the highest 184 incorporation of the glycoproteins into the particles (SI Figure 1B) . This same ratio was optimal 185
for the EEEV and WEEV E1/E2 glycoproteins (SI Figure 1C Figure 1A) . VLPs bearing glycoproteins for two other 196 encephalitic alphaviruses, EEEV and WEEV, were generated in an analogous fashion. They 197 were characterized by both western blot (SI Figure 1C) and ELISA (data not shown). CHIKV 198
VLPs were developed using an alternate VLP architecture that is dependent on the ability of 199 CHIKV capsid and envelope proteins to spontaneously drive VLP formation (28). Relying on 200 this organic approach, CHIKV VLPs were generated and characterized by both western blot (SI 201 Figure 1C ) and ELISA (data not shown). NHP sera with the VCMs on the MAGPIX, the limit of detection (LoD) was determined to be 209 at a 1 × 10 5 dilution in assay buffer ( Figure 3A ). Signal at this dilution was significantly higher 210 when compared to the same dilution of negative NHP sera (t-test; p<0.0001). The VEEV VCM 211 MAGPIX assay was two orders of magnitude more sensitive toward IgG detection than 212 traditional 96-well ELISA assays using inactivated TC-83 cell lysate or VEEV VLP direct 213 capture antigens ( Figure 3B) . 214
Characterization of Alphavirus VCMs in Singleplex and Multiplex Formats 215
Given the success of coupling and testing the VEEV VCMs, the three other alphavirus VLPs, 216 namely EEEV, WEEV, and CHIKV, were coupled to Magplex beads at a loading concentration 217 of 10 µg/million beads and screened against known IgG positive NHP sera in a singleplex format 218 ( Figure 3C ). The limit of detection of each singleplex alphavirus VCM assay was similar to that 219 observed in the proof of concept test with the VEEV VCMs at a 1 × 10 5 serum dilution. While 220 LoD was not affected by multiplexing the alphavirus VCMs and interrogating individual NHP 221 sera (SI Figure 2) , it was necessary to determine whether the assay would be specific for the 222 etiologic agent or whether crossreactivity would be observed (19). VEEV, EEEV, WEEV, and 223 CHIKV NHP sera were screened for IgG using a mixture of the four alphavirus VCMs (Figure  224 3D). At a 1:100 dilution of each NHP sera, some crossreactivity was observed as signal was 225 significantly above baseline for several of the non-correlative VCM-NHP sera pairings, most 226 notably between the VEEV NHP sera and the WEEV VCM; however, much of this 227 crossreactivity diminished at a 1:1,000 dilution of sera in assay buffer (SI Figure 3) . 228
Diagnostic Utility of Alphavirus VCMs for Animal Models and Human Clinical Samples 229
While the VCMs proved to be highly sensitive for detection of IgG in convalescent NHP sera, 230 the diagnostic utility of such a platform lies in its sensitivity toward IgM detection in sera from 231 both animal models and human clinical samples at early time points post-infection. The presence 232 of pathogen-specific IgM represents the earliest antibody response of an organism to infection. 233
As the course of infection progresses toward convalescence, the presence of IgM generally 234 decreases as IgG rises to dominate the humoral response (29). VEEV, EEEV, and WEEV NHP 235 sera (n=4 for each cohort) at multiple time points post-challenge were screened using a triplex 236 V/E/WEEV VCM assay. Anti-VEEV and anti-WEEV IgM response over baseline was observed 237 at days 5, 7 and 9 post-infection (Figure 4) . Interestingly, no anti-EEEV IgM response was 238 observed at any time point (data not shown). This was potentially due to the EEEV aerosol 239 challenge model used, which resulted in 75% lethality by day 5 post-exposure and 100% by day 240 7. Some IgM crossreactivity was observed when the time points were screened in the triplex 241 assay, most notably that of the EEEV VCMs with the VEEV NHP sera (SI Figure 4) . 242
Clinical samples from human vaccinations were screened with the same V/E/WEEV triplex 243 VCM assay for the presence of anti-viral-IgG. Thirty-two total samples were screened, where 16 244 were known negatives, a cohort of 10 were vaccinated with VEEV (TC-83), EEEV, and WEEV 245 vaccines, and a cohort of 6 with VEEV IND vaccine only ( Figure 5 ). The VEEV vaccine used 246 was live-attenuated TC-83 whereas the EEEV and WEEV vaccines were both formalin-247 inactivated. The V/E/WEEV VCM triplex had a sensitivity and specificity of 100%, with 0% 248 false positive and false negative rates, for detection of anti-V/E/WEEV IgG in the triple vaccine 249 cohort. For the cohort of 6 VEEV only vaccinations, the V/E/WEEV triplex assay had a 250 sensitivity and specificity of 100% toward VEEV IgG detection, but a false positive rate of 6% 251 and 11% for the EEEV and WEEV assays, respectively. 252
To further explore alphavirus crossreactivity, human clinical sera was screened using a 253 VEEV/CHIKV duplex VCM assay for the presence of anti-IgG and IgM antibodies. In developing countries, access to sensitive and sustainable diagnostics at healthcare facilities 266 can be a key determinant between controlling isolated cases of emerging or re-emerging 267 infectious disease or progression to an outbreak (12, 30) . Enveloped viruses cause the vast 268 majority of pathogenic viral diseases affecting human populations. Glycoproteins on the surface 269 of these viruses typically elicit robust antibody responses and therefore often represent the best 270 target antigen for detecting the serological response to these infectious agents. We developed a 271 multiplexed immunodiagnostic assay for detecting antibody response to these glycoproteins in 272 the context of alphavirus infections. Alphaviruses, which are members of the Togaviridae 273 family, are of concern both as emerging, enzootic pathogens and as biothreat agents (31). While 274 VEEV is a NIAID priority B pathogen and an area of concern for biodefense agencies, CHIKV 275 is a major global health concern, as its widespread prevalence leads to severe disease burden and 276 long-term disability (19). We designed a novel immunodiagnostic reagent for detection of anti-277 glycoprotein antibody responses to VEEV infection and demonstrated how the methodology can 278 be extended to additional alphaviruses such as EEEV, WEEV, and CHIKV. In an effort to meet 279 the key criteria needed for effective serological surveillance and clinical diagnostic protocols for 280 these pathogens and other biothreats, we aimed to rationally design the VCM reagent to be safe, 281 sensitive, flexible, and, most importantly, sustainable when used in field-forward platforms. 282
While many traditional immunoassays utilize inactivated viral preparations or recombinant 283 antigens as capture reagents, these reagents can be costly to produce, lack structural fidelity to 284 native particle-associated antigen, and, in the case of inactivated BSL3/4 agents, require high 285 level biocontainment for production and inactivation. Using VLPs as capture antigens is highly 286 advantageous, since they are easy and inexpensive to produce, inherently safe, and maintain 287 native structural antigen conformation. Integrating the surface glycoproteins onto either a 288 heterologous retroviral particle core or a homologous core (i.e. CHIKV) was a rational approach 289 for creating diagnostically useful, membrane-stabilized glycoprotein targets for 290 immunodiagnostic applications. As our results demonstrated, these particles were simple to 291 produce and reactive against seropositive NHP sera and glycoprotein-specific mAbs (Figure 2) . 292
The VCM as an antibody target combined with the MAGPIX to detect antibodies to multiple 293 targets simultaneously in a single sample is an extremely flexible platform technology. VEEV 294 NHP sera, screened with VEEV VCMs, yielded an IgG LoD at serum dilution of 1 × 10 5 (Figure  295 3A). A marked improvement over traditional ELISA was also observed with the VCM 296 approach, not only in a reduction in time-to-answer, but with a two-order magnitude of increased 297
IgG sensitivity ( Figure 3B ). As an extension of this concept, three other alphavirus VCMs were 298 developed and characterized-each yielding IgG LoDs at serum dilutions 1 × 10 5 for 299 corresponding NHP serum ( Figure 3C ). When assays were multiplexed for VEEV, EEEV, 300 WEEV, and CHIKV antibody detection, there was no observed loss in sensitivity with the 301 combined assay components (SI Figure 2) . Some anti-glycoprotein IgG crossreactivity amongst 302 members of the New-World alphaviruses was observed when sera were screened with the 303 quadruplex assay; however, this was to be expected as the glycoproteins, in particular E1, of 304 some alphavirus family members share regions of homology and possess conserved epitopes 305 (32). IgM responses in NHPs to VEEV and WEEV challenge were observed starting at day 5 and 306 day 7 post-challenge, respectively (Figure 4 ). Minimal crossreactivity with the VEEV and 307 EEEV VCMs was observed with the WEEV sera, but significant crossreactivity was observed on 308 the EEEV VCM with the VEEV sera. Nonetheless, it was apparent there was a strong correlation 309 between the VCM with the highest signal response and the etiologic agent of the screened sera. 310
Pairing this multiplexed VCM immunoassay with PCR, in an integrated diagnostic approach, 311 would lead to the highest confidence in specific pathogen identification. 312
Human sera from equine encephalitic virus vaccines were screened alongside a cohort of true 313 negatives with a triplex V/E/WEEV VCM assay to determine assay performance metrics for IgG 314 detection ( Figure 5 ). For the cohort of 10 vaccinations that received a trivalent V/E/WEEV 315 vaccine, the assay had a sensitivity and specificity of 100% with 0% false positive and false 316 negative rates. This was to be expected as it was known that this cohort received the trivalent 317 vaccine; however the assay served to confirm seroconversion. For the cohort of 6 vaccinations 318 that received only the VEEV vaccine, the triplex assay had a sensitivity and specificity of 100% 319 for the VEEV assay, but the false positive rates for the EEEV and WEEV assay components 320 were 6% and 11%, respectively. This observation is likely attributed to the previously noted 321 crossreactivity within IgG positive equine encephalitic sera (33, 34) . Despite this crossreactivity, 322 there was again strong overall signal on the VEEV VCM, correlating to the etiologic agent of the 323 vaccine. When human clinical sera from VEEV and CHIKV infection were screened in a duplex 324 with VEEV and CHIKV VCMs, less crossreactivity was observed, specifically with IgM 325 detection ( Figure 6 ). This would suggest that differential diagnosis by IgM detection is 326 achievable for identifying Old-World versus New-World alphaviruses, which would be 327 significant in regions where both the equine encephalitic viruses and CHIKV are endemic. 328 A sustainable, flexible, and robust immunoassay such as the VCM platform presented here 329 utilized on a field-forward platform such as the MAGPIX® has the potential to greatly improve 330 diagnostic capacity for both diagnostic and serosurveillance scenarios, as this platform affords 331 higher throughput, faster read times, reduced sample consumption, and increased sensitivity to 332 reach a diagnostic result as compared to screening by traditional ELISA methods. Many overseas 333 centralized laboratories are currently able to perform basic ELISA immunoassays, but are often 334 limited to commercially available kits. These kits are costly, time consuming to run, variable in 335 performance from lot to lot, and difficult to keep in stock, as manufacturers often discontinue 336 products or have long purchasing lead times. We were able to screen multiple serum sample 337 types using several multiplexed assay iterations in two hr on the same plate using only 2 µL of 338 each sample, whereas up to 24 hr, separate plates, and up to 10 µL of each sample would be 339 required to achieve the same result with a traditional 96-well plate ELISA. While we 340 demonstrated the ability of our VCM platform to detect of alphavirus immune responses in 341 animal models, as well as human clinical samples (both natural infection and vaccinated), this 342 VCM platform technology could be extended to other virus families, particularly those endemic 343 in central and western sub-Saharan Africa, to create regional-specific serosurveillance or 344 diagnostic panels for use at centralized testing facilities. In particular, the VCM approach will be 345 useful for diagnostic strategies targeting antibody response against other arbovirus envelope 346 targets (e.g. dengue virus E, etc.), whose glycoproteins are frequently difficult to produce in 347 recombinant form (35). Incorporation of sustainable and sensitive immunoassay reagents such as 348
VCMs into field-forward technologies will become increasingly important in global surveillance 349 and diagnostic efforts to limit the spread of infectious viral diseases. Research on human subjects was conducted in compliance with DoD, Federal, and State statutes 365 and regulations relating to the protection of human subjects, and adheres to principles identified 366 in the Belmont Report (1979) . All data and human subjects research were previously deidentified 367 and given a "research not involving human subjects" determination by the USAMRIID Office of challenged NHPs, respectively, at Days 0, 3, 5, 7, and 9 post-challenge. All NHP sera was 513 diluted 1:100 in assay buffer. 514 
